DCF — CROZER CHESTER MEDICAL CENTER
Enterprise Value: $-1.3B
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-1.3B
Enterprise Value
$-411.9M
PV of Cash Flows
$-929.0M
PV of Terminal Value
$-1.5B
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $473.4M | $-90.2M | -19.0% | $-110.3M | $-100.3M |
| Year 2 | $487.6M | $-88.1M | -18.0% | $-108.7M | $-89.8M |
| Year 3 | $502.3M | $-85.7M | -17.0% | $-107.0M | $-80.4M |
| Year 4 | $517.3M | $-85.7M | -17.0% | $-107.6M | $-73.5M |
| Year 5 | $532.8M | $-86.9M | -16.0% | $-109.5M | $-68.0M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-1.3B. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$459.6M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.19561683608431507
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5